| 1. |
- Ruilope, LM, et al.
(författare)
-
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
- 2019
-
Ingår i: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
-
Tidskriftsartikel (refereegranskat)abstract
- <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
|
|
| 2. |
- Manova, S., et al.
(författare)
-
Experimental investigation of heat transfer characteristics in a miniature flat heat pipe with multi-channels
- 2024
-
Ingår i: International Journal of Heat and Mass Transfer. - : Elsevier Ltd. - 0017-9310 .- 1879-2189. ; 221
-
Tidskriftsartikel (refereegranskat)abstract
- The heat transfer characteristics of a miniatured flat heat pipe (MFHP) with multi-channels, featuring a port diameter of 1.18 mm, is investigated experimentally. Various operating parameters are considered, including the working fluid volume (Vf = 1.5, 2.5, and 3.5 ml), length of the liquid reservoir (Lres = No reservoir, 5, and 10 mm), orientation such as axial face (αa) or lateral side (αl), inclination angles (α = −15 to 90o), and cooling water flow rates (ṁi = 10, 15, and 20 LPH). Based on the experiments, the optimal values for the working fluid volume, reservoir length, and flow rate are determined as Vf = 2.5 ml, Lres = 5 mm, and ṁi = 20 LPH, respectively. Further analysis reveals that, the heat dissipation rate for the axial face is significantly higher than that of the lateral side, with an average percentage increase of 35.4 %. However, the lateral side outperforms the axial face in terms of stabilizing the evaporator wall temperature, reducing fluctuations by an average of 24.5 %. Moreover, the presence of multi-channels allows the MFHP in axial face orientation to dissipate a maximum heat load of 15 W against gravity at an inclination angle of αa = −15o. Finally, the variations in MFHP operation based on the orientation and its underlying physical mechanisms that contribute to enhancing heat transfer are discussed.
|
|
